The Valley Desk

NCT04049266 · Interventional trial

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Overall registry status Terminated

Phase 2 · Phase 3

Conditions Wet Macular Degeneration

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov